Idelalisib-Rituximab Combo Found Active in R/R CLL Regardless of Complex Karyotype
Presence of a complex karyotype did not affect progression-free or overall survival.
All articles by Leah Lawrence
Germline Testing Should Be Routinely Conducted in Patients With Metastatic Breast Cancer
High prevalence of pathogenic/likely pathogenic variants supports wider testing.
CheckMate 214: Long-Term Results Confirm Superiority of Nivolumab Plus Ipilimumab for mRCC
Superiority of the regimen was shown in intermediate- and poor-risk groups, as well as in intention-to-treat populations.
Germline BRCA2 Mutations Linked to Pediatric Lymphomas
Survivors of NHL should be offered genetic counseling.
HLA-B27 Positivity Did Not Influence CLL, SLL Outcomes
Further studies needed to look at relevance outside of the transplant-eligible population.
CDK4/6 Inhibitors Should Be Standard First-Line Treatment for Metastatic HR+ Breast Cancer, Concludes Expert
Emerging overall survival data show a benefit of this type of drug across a variety of patient subgroups.
Real-World Data Useful to Quantify Benefit of New Cancer Therapies
Data could support regulatory, payer decision making.
Experts Recommend Cytologic Test Every 3 Years, High-Risk HPV Test Every 5 Years
A new study challenges the recommended use of cotesting for cervical cancer screening.
Unrelated Donor Transplant Yields Better Results than Cord Blood in R/R Acute Myeloid Leukemia
Cord blood transplant resulted in poorer nonrelapse mortality and leukemia-free survival.
Rituximab Biosimilar CT-P10 Equivalent as Monotherapy for Follicular Lymphoma
US FDA recently approved rituximab biosimilar as monotherapy and in combination with chemotherapy.
Next post in ASH Annual Meeting 2018
